Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jun 2;83(1):98–103. doi: 10.1054/bjoc.2000.1216

Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response

D A Cameron 1, W M Gregory 2, A Bowman 1, E D C Anderson 3, P Levack 1, P Forouhi 3, R C F Leonard 1
PMCID: PMC2374548  PMID: 10883676

Abstract

Although clinical response to primary chemotherapy in stage II and III breast cancer is associated with a survival advantage, it is the degree of pathological response in the breast and ipsilateral axilla that best identifies patients with a good long-term outcome. A mathematical model of the initial response of 39 locally advanced tumours to anthracycline-based primary chemotherapy has been previously shown to predict subsequent clinical tumour size. This model allows for the possibility of primary resistant disease, the presence of which should therefore be associated with a worse outcome. This study reports the application of this model to an additional five patients with locally advanced breast cancer, as well as to 63 patients with operable breast cancer, and confirms the biological reality of the model parameters for these 100 breast cancers treated with primary anthracycline-based chemotherapy. The tumours that responded to chemotherapy had higher cell-kill (P< 0.0005), lower resistance (P< 0.0001) and slower tumour regrowth (P< 0.002). Furthermore, ER-negative tumours had higher cell-kill (P< 0.05), as compared with ER-positive tumours. All patients with a pathological complete response had zero resistance according to the model. Furthermore, the long-term implication of chemo-resistant disease was demonstrated by survival analysis of these two groups of patients. At a median follow-up of 3.7 years, there was a statistically significantly worse survival for the 37 patients with locally advanced breast cancer identified by the model to have more than 8% primary resistant tumour (P< 0.003). The specificity of this putative prognostic indicator was confirmed in the 63 patients presenting with operable disease where, at a median follow-up of 7.7 years, those women with a resistant fraction of greater than 8% had a significantly worse survival (P< 0.05). Application of this model to patients treated with neoadjuvant chemotherapy may allow earlier identification of clinically significant resistance and permit intervention with alternative non-cross-resistant therapies such as taxoids. © 2000 Cancer Research Campaign

Keywords: breast cancer, mathematical model, response, treatment, resistance, survival

Full Text

The Full Text of this article is available as a PDF (73.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aas T., Børresen A. L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lønning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996 Jul;2(7):811–814. doi: 10.1038/nm0796-811. [DOI] [PubMed] [Google Scholar]
  2. Anderson E. D., Forrest A. P., Hawkins R. A., Anderson T. J., Leonard R. C., Chetty U. Primary systemic therapy for operable breast cancer. Br J Cancer. 1991 Apr;63(4):561–566. doi: 10.1038/bjc.1991.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bonadonna G., Valagussa P., Brambilla C., Ferrari L. Preoperative chemotherapy in operable breast cancer. Lancet. 1993 Jun 5;341(8858):1485–1485. doi: 10.1016/0140-6736(93)90933-8. [DOI] [PubMed] [Google Scholar]
  4. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. doi: 10.1093/jnci/82.19.1539. [DOI] [PubMed] [Google Scholar]
  5. Bélembaogo E., Feillel V., Chollet P., Curé H., Verrelle P., Kwiatkowski F., Achard J. L., Le Bouëdec G., Chassagne J., Bignon Y. J. Neoadjuvant chemotherapy in 126 operable breast cancers. Eur J Cancer. 1992;28A(4-5):896–900. doi: 10.1016/0959-8049(92)90145-r. [DOI] [PubMed] [Google Scholar]
  6. Cameron D. A., Anderson E. D., Levack P., Hawkins R. A., Anderson T. J., Leonard R. C., Forrest A. P., Chetty U. Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy. Br J Cancer. 1997;76(8):1099–1105. doi: 10.1038/bjc.1997.514. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cameron D. A., Gregory W. M., Bowman A., Leonard R. C. Mathematical modelling of tumour response in primary breast cancer. Br J Cancer. 1996 Jun;73(11):1409–1416. doi: 10.1038/bjc.1996.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Fisher B., Brown A., Mamounas E., Wieand S., Robidoux A., Margolese R. G., Cruz A. B., Jr, Fisher E. R., Wickerham D. L., Wolmark N. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997 Jul;15(7):2483–2493. doi: 10.1200/JCO.1997.15.7.2483. [DOI] [PubMed] [Google Scholar]
  9. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E. R., Wickerham D. L., Begovic M., DeCillis A., Robidoux A. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998 Aug;16(8):2672–2685. doi: 10.1200/JCO.1998.16.8.2672. [DOI] [PubMed] [Google Scholar]
  10. Forouhi P., Dixon J. M., Leonard R. C., Chetty U. Prospective randomized study of surgical morbidity following primary systemic therapy for breast cancer. Br J Surg. 1995 Jan;82(1):79–82. doi: 10.1002/bjs.1800820127. [DOI] [PubMed] [Google Scholar]
  11. Gabra H., Cameron D. A., Lee L. E., Mackay J., Leonard R. C. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. Br J Cancer. 1996 Dec;74(12):2008–2012. doi: 10.1038/bjc.1996.668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gregory W. M., Reznek R. H., Hallett M., Slevin M. L. Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume. Br J Cancer. 1990 Oct;62(4):671–675. doi: 10.1038/bjc.1990.354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Makris A., Powles T. J., Dowsett M., Osborne C. K., Trott P. A., Fernando I. N., Ashley S. E., Ormerod M. G., Titley J. C., Gregory R. K. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res. 1997 Apr;3(4):593–600. [PubMed] [Google Scholar]
  14. Mauriac L., Durand M., Avril A., Dilhuydy J. M. Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre. Ann Oncol. 1991 May;2(5):347–354. doi: 10.1093/oxfordjournals.annonc.a057953. [DOI] [PubMed] [Google Scholar]
  15. McGuire W. L. Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst. 1991 Feb 6;83(3):154–155. doi: 10.1093/jnci/83.3.154. [DOI] [PubMed] [Google Scholar]
  16. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):547–552. doi: 10.1200/JCO.1995.13.3.547. [DOI] [PubMed] [Google Scholar]
  17. Scholl S. M., Pierga J. Y., Asselain B., Beuzeboc P., Dorval T., Garcia-Giralt E., Jouve M., Palangié T., Remvikos Y., Durand J. C. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer. 1995 Nov;31A(12):1969–1975. doi: 10.1016/0959-8049(95)00454-8. [DOI] [PubMed] [Google Scholar]
  18. Smith I. E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., Ramage F., Robertshaw H., Sacks N., Ebbs S. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb;13(2):424–429. doi: 10.1200/JCO.1995.13.2.424. [DOI] [PubMed] [Google Scholar]
  19. Thomlinson R. H. Cancer: the failure of treatment. Br J Radiol. 1987 Aug;60(716):735–751. doi: 10.1259/0007-1285-60-716-735. [DOI] [PubMed] [Google Scholar]
  20. Thomlinson R. H. Measurement and management of carcinoma of the breast. Clin Radiol. 1982 Sep;33(5):481–493. doi: 10.1016/s0009-9260(82)80153-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES